Industry News
August 29, 2026
1 min read
9 views

“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Original Source

TechCrunch AI

by Connie Loizos
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thi

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

Tags:AI

Original Content Credit

This summary is sourced from TechCrunch AI. For the complete article with full details, research data, and author insights, please visit the original source.

Visit TechCrunch AI

Related Articles